p-200 - final
TRANSCRIPT
www.asthma-copd.co.uk Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
ACADEMIC & GROUP DISCOUNTS AVAILABLE @SMIPHARM #asthmacopdsmi
SMi proudly present their 13th annual conference on…
Asthma & COPD Leading strategies to novel treatments and solutions
Holiday Inn Kensington Forum, London, UK
HIGHLIGHTS IN 2017: • Updates from the MHRA on the regulatory challenges
to developing inhalation devices
• Overcome hurdles to the success of new devices with Boehringer Ingelheim
• Janssen’s innovative approaches to COPD interception
• Track the emerging trends in targeted treatment with biomarkers and biologics with MedImmune
• ‘Real time data collection’ – an exclusive case study presentation on GSK’s pioneering ‘Salford Lung study’
PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPSTuesday 28th March 2017, Holiday Inn Kensington Forum, London, UK
CHAIRS: Day 1 - Wisia Wedzicha, Professor of Respiratory Medicine, Imperial College London
Day 2 - Stephen Beckman, Head of Global Respiratory and Allergy, Mylan
FEATURED SPEAKERS: • Quan Yang, Pharmaceutical Assessor, MHRA • David Leather, Global Medical Affairs Leader,
GlaxoSmithKline • Stefan Leiner, Chemical-Pharmaceutical Expert,
Boehringer Ingelheim • Neelima Khairatkar Joshi, Senior Vice President & Head of
Drug Discovery, Glenmark Pharmaceuticals • Christopher Stevenson, Venture Leader COPD Interception,
Janssen • Frank Thielmann, Operational Lead Inhalation New Solids,
Novartis • Ewan Walters, Medical Director, Teva UK • Outi Vaarala, Head of Translational Biology, AstraZeneca
REGISTER BY 30TH NOVEMBER FOR A £400 DISCOUNTREGISTER BY 16TH DECEMBER FOR A £200 DISCOUNT REGISTER BY 31ST JANUARY FOR A £100 DISCOUNT
WORKSHOP AThe future of Asthma & COPD management; from
connected inhalers to therapy management 08.30 – 12.30
Workshop Leader: Vaishali Kamat, Director of Digital Health, Cambridge Consultants
WORKSHOP BInnovative approaches to COPD – Proactive, not reactive, strategies
13.30 – 17.30 Workshop Leader:
Christopher Stevenson, Venture Leader COPD Interception, Janssen
CONFERENCE: 29TH - 30THWORKSHOPS: 28TH
MAR 2017
Asthma & COPD Day One | Wednesday 29th March 2017
08.30 Registration & Coffee
09.00 Chairman’s Opening Remarks Wisia Wedzicha, Professor of Respiratory Medicine,
Imperial College London
OPENING ADDRESS 09.10 EU and UK regulatory considerations for the development
of inhaled products • EU and UK regulatory hurdles to developing and
registering a generic inhalation product • Regulations for inhalation drug development, including
combination considerations • Regulatory updates on the device component of a
medicinal product • How does device type affect the development and
approval process? Quan Yang, Pharmaceutical Assessor, MHRA
09.50 Overcoming challenges to industry in the device development process
• Moving away from generic development • Taking age group into consideration when developing a
device; considerations for paediatric and elderly patients • Incorporating clinical trials as a key step in obtaining
device approval • USP regulatory update on spacers in new devices Stefan Leiner, Chemical-Pharmaceutical Expert,
Boehringer Ingelheim
10.30 Morning Coffee
11.00 From molecule to medicine – formulation development and manufacturing of dry powder inhalation products
• Device and formulation systems and their selection • Drug substance – product relationship. How does
performance in vitro relate to performance in vivo? • Challenges in the manufacturing of DPI systems • Future trends in inhaled drug delivery Frank Thielmann, Operational Lead Inhalation New Solids,
Novartis
11.40 Matching device and treatment to disease stage; considerations for the treatment of asthma
• Clinical development of novel inhalers – trends with case study examples
• Challenges to the development of novel inhalers; increased cost of development vs. improved performance and decreased cost to NHS
• Targeting severe exacerbation with novel monoclonal antibodies
- Mechanism for targeting and exacerbation reduction - Knock on effects to NHS and pricing strategies Ewan Walters, Medical Director, Teva UK
12.20 Networking Lunch
13.30 Case study; Inhaled calcilytics for infl ammatory lung disease
• The calcium-sensing receptor as a novel drug target for
asthma and COPD
• Calcilytics prevent asthma-associated airways hyper-
responsiveness and infl ammation
• Calcilytics in eosinophilic and neutrophilic models of
infl ammatory lung disease
• Targeting a potential root of infl ammatory lung disease
Daniela Riccardi, Professor of Physiology, Cardiff University 14.10 Application of biomarkers and patients characteristics to
personalise treatment of Asthma & COPD • Current clinical unmet needs in Asthma and COPD
• How useful are biomarkers in identifying disease
phenotype and disease course?
• Multidimensional approach to deliver the right treatment
to the right patient
• Using biomarkers to develop targeted therapeutics for
Asthma and COPD
Marianna Alacqua, Senior Global Medical Affairs Leader of
Respiratory Biologics, AstraZeneca
14.50 Afternoon Tea
15.20 Biologics; targeted treatment to targeted cases • Case study
• Current patient selection strategies for identifying best
treatment
• Moving towards personalised treatments for asthma and
COPD
Donna Finch, Principle Scientist, MedImmune
16.00 Identifying eosinophil biomarkers for targeted therpeutic treatment of COPD
• Blood eosinophils as biomarkers in COPD
• How blood eosinophils can be used to adjust treatment
approach
• Implications for future treatment strategies
Wisia Wedzicha, Professor of Respiratory Medicine, Imperial College London
16.40 Chairman’s Closing Remarks and Close of Day One
REGULATORY UPDATE FOR INHALATION DEVICE DEVELOPMENT
THERAPEUTIC DEVELOPMENTS - PART 1
Supported byOffi cial Publications
Register online at www.asthma-copd.co.uk
SPONSORSHIP AND EXHIBITION OPPORTUNITIESSMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy.
Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specifi c to your industry. Should you wish to join the increasing number of companies benefi ting from sponsoring our conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or email: [email protected]
MARKETING OPPORTUNITIESWant to know how you can get involved? Interested in promoting your services to this market?
Contact – Zoe Gale SMi Marketing on +44 (0) 20 7827 6132 or email: [email protected]
Asthma & COPD Day Two | Thursday 30th March 2017
08.30 Registration & Coffee
09.00 Chairman’s Opening Remarks Stephen Beckman, Head of Global Respiratory and
Allergy, Mylan
09.10 Integration of innovation and opportunity in COPD • Innovation serving new ways to treat and manage
unique sub populations in COPD • Impact of RX and GX solutions in COPD and Asthma • How advanced delivery solutions will impact the market • Changes in payer and provider care impacts innovation • What trends will most affect the next ten years in Asthma
and COPD Stephen Beckman, Head of Global Respiratory and
Allergy, Mylan 09.50 Early interception of COPD • Focussing on early identifi cation of COPD using targeted
biomarkers and identifying related disease pathways • Impact of early interception to later disease course,
progression and treatment strategies • Integrating novel therapeutics and diagnostics to
address patient susceptibility to COPD Christopher Stevenson, Venture Leader COPD Interception,
Janssen
10.30 Morning Coffee
11.00 Novel anti-infl ammatory approaches in the treatment of COPD
• Lung infl ammation orchestrations in COPD • Past and present approaches to anti-infl ammatory
approaches • Breaking down infl ammation; from animals to man to
patients: mind the gap • Will novel targets deliver novel therapeutics in COPD Neelima Khairatkar Joshi, Senior Vice President & Head of
Drug Discovery, Glenmark Pharmaceuticals
11.40 Phenotyping Asthma and COPD disease types • Rethinking diagnosis criteria for asthma and COPD
based on genetic phenotyping • Impacts of phenotyping on treatment type, and
individuality of treatment • Patient stratifi cation using phenotypic patient subsets Neil Barnes, Global Medical Head, GlaxoSmithKline
12.20 Networking Lunch
SPOTLIGHT SESSION
13.30 ‘Real time’ data collection
– The Salford Lung study
• A fi rst of its kind study to demonstrate the
effectiveness of Relvar Ellipta in COPD
and asthma patients
• Study overview, aims and background
• Benefi ts of real time data collection – setting future
trends?
- Comparing the representativeness of effectiveness
studies vs randomised double blind controlled studies
- Drivers of effectiveness; for example adherence, co-
morbidity and age
• Implications of integrated health systems
- Changing patient ~ clinician relationships
David Leather, Global Medical Affairs Leader,
GlaxoSmithKline
14.10 Recent advances in drug development and treatments for
Asthma and COPD
• Current treatment options for asthma and COPD
• Moving forward: Insilico, PK and PD modelling and
simulation methods for evaluating respiratory drugs
• Assessing drug performance and dose response
relationships using a PKPD approach
• Increasing weight of evidence for the evaluation of the
safety and effi cacy of respiratory drugs
Beverley Patterson, Associate Director of Inhalation Clinical
R&D, Actavis
14.50 Afternoon Tea
15.30 Identifying novel biomarkers to determine patient
response disease types
• Development of novel biomarkers for eosinophilic
respiratory disease and mixed T-cell asthma
• Identifying epigenetic drivers in respiratory disease
• Towards more targeted treatment strategies for
respiratory diseases
Outi Vaarala, Head of Translational Biology, AstraZeneca
16.10 Chairman’s Closing Remarks and Close of Day Two
THERAPEUTIC DEVELOPMENTS - PART 2
COPD UPDATES
Supported by
Alternatively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
MARKETING OPPORTUNITIESWant to know how you can get involved? Interested in promoting your services to this market?
Contact – Zoe Gale SMi Marketing on +44 (0) 20 7827 6132 or email: [email protected]
SPOTLIGHT CASE STUDY
The future of Asthma & COPD management; from connected inhalers
to therapy management
Workshop Leaders: Vaishali Kamat, Director of Digital Health,
Cambridge Consultants
HALF-DAY POST-CONFERENCE WORKSHOPTuesday 28th March 2017
08.30 – 12.30Holiday Inn Kensington Forum, London, UK
Overview of Workshop:This half day workshop will explore how the treatment of Asthma and COPD is evolving. The discussion will focus on how personalised medicine and enhanced user experience can improve patient outcome. The workshop will provide insights on emerging technology trends relevant to the future of respiratory drug delivery devices and highlight the manufacturing and development challenges one might face. Specifi cally, the workshop will examine the impact that wireless technologies, sensors, wearables and data analytics will have in a future which will undoubtedly require pharmaceutical companies to develop more holistic treatment solutions that support 1) patients to take control of their disease state and 2) healthcare professionals provide more effi cient care.
Reasons for attending• Discuss challenges and opportunities in COPD and
Asthma treatment • Hear about emerging trends in digital health and
their relevance to respiratory drug delivery• Review lessons learned and obtain top tips on
development connected drug delivery solutions
Programme:
08.30 Registration & Coffee
09.00 Workshop leader introduction
09.10 Current gaps in the treatment of COPD and Asthma • Compliance • Patient outcomes • Reimbursement/ competiveness
09.50 Emerging trends in digital health • Delivering better user experience • Role of sensors, wearables and digital
biomarkers • Data analytics and digital services
10.30 Morning Coffee
11.00 The future of COPD and Asthma • Evolution of connected drug delivery devices • Development and manufacturing
considerations • Regulatory considerations
12.20 Discussion
12.30 Close of Workshop
About the Workshop Leader:Vaishali Kamat is a director and Head of Digital health at Cambridge Consultants, a leading technology and product development fi rm. Over the past 6 years she has helped clients develop ecosystem solutions comprising of wireless medical devices, mobile applications and services to improve health outcomes and increase revenues. She brings signifi cant domain and technical expertise in the rapidly evolving digital health space including an understanding of the regulations and insight into fi nancial models and market players. Vaishali is an engineer by training and has over 18 years’ experience in medical device design and has several published articles to her credit. Prior to joining Cambridge Consultants, she worked in diagnostic imaging for GE Healthcare.
About the Organisation:Cambridge Consultants develops breakthrough products, creates and licenses IP, and provides business consultancy in technology-critical issues for clients worldwide. For more than 50 years, we have been helping clients turn business opportunities into commercial successes, whether they are launching fi rst-to-market products, entering new markets or expanding existing markets through new technologies. Our auto-injector, inhaler and injection device development programmes extend from concept creation though to industrialisation, with a ‘quality by design’ approach and full compliance with international regulatory standards.
Innovative approaches to COPD – Proactive, not reactive, strategies
Workshop Leader: Christopher Stevenson,
Venture Leader COPD Interception, Janssen
HALF-DAY POST-CONFERENCE WORKSHOPTuesday 28th March 2017
13.30 – 17.30Holiday Inn Kensington Forum, London, UK
Overview of Workshop:COPD is the 3rd leading cause of death worldwide. It is also a growing burden to healthcare services, in terms of number of unscheduled visits, comorbidities and disease prevalence. It is clear that fresh, proactive approaches to tackling COPD are necessary. This workshop affords exploration and insight into the emerging efforts to catch and treat COPD in the early stages of the disease. Janssen’s Christopher Stevenson leads a pioneering team focussed on interception of COPD. This workshop will comprehensively address the emerging trends, benefi ts and ideal outcomes of COPD interception. This trend could be a pivotal development in tackling COPD.
Reasons for attending • Map emerging trends and new approaches to tackling
COPD• Discuss best methods for earlier identifi cation of COPD • See the benefi ts of intervening at earlier stages of COPD• COPD prevention – a feasible possibility for the near
future? • Identify key areas of future development and future
trends in addressing COPD
Programme:
14.00 Session 1 – Shifting towards early diagnosis and interception of COPD
• Emerging trends in COPD • Approaches to earlier identifi cation, intervention
and monitoring COPD
14.15 Discussion
14.20 Session 2 – Defi ning the early molecular events in the pathogenesis of COPD
• Molecular biomarkers for earlier diagnosis of COPD - Is a molecular screening test possible? • Insights into molecular causes of COPD
14.50 Discussion
15.10 Afternoon Tea
15.40 Session 3 – Current state-of-the-art overview of COPD imaging biomarker efforts
• CT biomarkers for earlier diagnosis of COPD - Considerations for diagnostic tests: Predictive
value, cost, test complexity • Imaging insights for stratifi cation of COPD
sub-types
16.10 Discussion
16.30 Session 3 – Implementing change in approaching COPD
• Biomarkers for monitoring disease progression – Lessons from current COPD cohorts
• Regulatory considerations of reclassifying COPD endpoints
• Next steps towards interception and prevention of COPD
17.00 Discussion
17.30 Workshop leaders’ comments and close of Workshop
About the Workshop Leader:Dr. Christopher Stevenson is the the COPD Venture Leader for the Janssen Disease Interception Accelerator (DIA). Chris is a health care innovator with nearly 20 years of experience spanning both industry and academia. He has previous respiratory discovery experience at GlaxoSmithKline, Hoffmann-La Roche and Novartis. Chris also held a faculty position at Imperial College London and is currently an honorary professor at the University of Southern Denmark. In his current role, Chris is leading efforts to identify the root cause(s) of COPD with the aim of intervening earlier than today’s clinically-accepted point of diagnosis and stop disease before it starts.
About the Janssen Pharmaceutical Companies At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by fi nding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it.
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:I agree to be bound by SMi’s Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received.Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not ‘share’ a place at an event. Please make separate bookings for each delegate.Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regretfully cancellation after this time cannot be accepted. We will however provide the conferences documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefi ngs we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifi cally to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability.Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme.Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here □ we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager [email protected] or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the attached letter.
Payment must be made to SMi Group Ltd, and received before the event, by one of the following methods quoting reference P-200 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment:
□ UK BACS Sort Code 300009, Account 00936418□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): LOYDGB21013, Account 00936418 IBAN GB48 LOYD 3000 0900 9364 18□ Cheque We can only accept Sterling cheques drawn on a UK bank.□ Credit Card □ Visa □ MasterCard □ American Express All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□Valid From □□/□□ Expiry Date □□/□□CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:I agree to be bound by SMi’s Terms and Conditions of Booking.
Card Billing Address (If different from above):
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on Document portal and literature distribution for all UK customers and for those EU Customers not supplying a registration number for their own country here. ______________________________________________________________________________________
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email [email protected]
EARLY BIRD DISCOUNT
□ Please contact me to book my hotelAlternatively call us on +44 (0) 870 9090 711, email: [email protected] or fax +44 (0) 870 9090 712
I cannot attend but would like to purchase access to the following Document Portal/paper copy documentation Price Total□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
Unique Reference Number
Our Reference LVP-200
DELEGATE DETAILS
Terms and Conditions of Booking
PAYMENT
VAT
CONFERENCE PRICES
DOCUMENTATION
VENUE Holiday Inn Kensington Forum,, 97 Cromwell Rd, London SW7 4DN, UK
ASTHMA & COPD Conference: Wednesday 29th & Thursday 30th March 2017, Holiday Inn Kensington Forum, London, UK
Workshops: Tuesday 28th March 2017, London, UK
4 WAYS TO REGISTERwww.asthma-copd.co.uk
FAX your booking form to +44 (0) 870 9090 712PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd, Ground & First Floor, 1 Westminster Bridge Road London, SE1 7XW, UK
□ Book by the 30th November to receive £400 off the conference price □ Book by the 16th December to receive £200 off the conference price□ Book by the 31st January to receive £100 off the conference price
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference & 2 Workshops £2697.00 + VAT £3236.40□ Conference & 1 Workshop A □ B □ £2098.00 + VAT £2517.60□ Conference only £1499.00 + VAT £1798.80□ 2 Workshops £1198.00 + VAT £1437.60□ 1 Workshop only A □ B □ £599.00 + VAT £718.80
PROMOTIONAL LITERATURE DISTRIBUTION □ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to the Document Portal. Presentations that are available for download will be subject to distribution rights by speakers. Please note that some presentations may not be available for download. Access information for the document portal will be sent to the e-mail address provided during registration. Details are sent within 24 hours post conference.